Eli Lilly and Company (LLY) News Today

Eli Lilly & Company (LLY) has seen its shares move today amid a mix of strong clinical trial data, favorable analyst actions, regulatory developments, and valuation debates. Key factors influencing the stock include:

• Positive Sentiment: Mounjaro delivered significant cardiovascular protection in a first-of-its-kind Phase 3 head-to-head trial against Trulicity, reducing major adverse cardiovascular events by 8% and all-cause mortality by 16%. Mounjaro proves more heart protective than Trulicity in trial of Eli Lilly diabetes drugs
• Positive Sentiment: Proposed Medicare and Medicaid coverage expansions for GLP-1 weight-loss therapies could significantly broaden Mounjaro’s addressable market. Eli Lilly (LLY) to Benefit from Proposed Coverage of Weight Loss Drugs by Medicare and Medicaid
• Positive Sentiment: Goldman Sachs maintained a Buy rating on LLY with a $883 price target, citing strong upcoming trial readouts and robust earnings projections. Positive Outlook for Eli Lilly & Co. Amid Key Trial Outcomes and Earnings Projections
• Positive Sentiment: Zacks notes that Lilly has the right setup for an earnings beat next week, with Wall Street expecting continued revenue and EPS growth. Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
• Positive Sentiment: Lilly’s new clinical study on LY4088044 could be a game-changer in drug safety evaluation, potentially opening a new platform for future pipeline candidates. Eli Lilly’s New Study on LY4088044: A Potential Game-Changer in Drug Safety Evaluation
• Positive Sentiment: A late-stage cancer trial showed Lilly’s experimental therapy outperformed AbbVie’s, reinforcing confidence in its oncology franchise. Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The Stock
• Positive Sentiment: Investment commentary on Seeking Alpha recommends trimming AI names to buy Lilly ahead of key data readouts, highlighting LLY’s defensive attributes. Trim Your AI Stocks And Buy Eli Lilly
• Neutral Sentiment: MarketBeat’s screener lists Eli Lilly among the top pharmaceutical stocks to follow, reflecting broad sector momentum. Top Pharmaceutical Stocks To Follow Today - August 1st
• Neutral Sentiment: Another MarketBeat alert includes LLY on a list of promising pharmaceutical names to watch, underscoring ongoing clinical catalysts. Promising Pharmaceutical Stocks To Add to Your Watchlist - July 31st
• Neutral Sentiment: MarketBeat notes LLY shares were up roughly 2.4% intraday, prompting a “time to buy?” discussion. Eli Lilly and Company (NYSE:LLY) Stock Price Up 2.4% – Time to Buy?
• Neutral Sentiment: LLY is set to report Q2 2025 earnings on August 7, with investors positioning ahead of results. Eli Lilly and Company (LLY) to Release Quarterly Earnings on Thursday
• Neutral Sentiment: An earnings preview on Seeking Alpha argues the worst may be behind Lilly, pointing to seasonal revenue trends and pipeline catalysts. Eli Lilly: The Worst May Be Already Over (Earnings Preview)
• Neutral Sentiment: Yahoo Finance reports LLY unveiled early Alzheimer’s and CLL trial data in partnership with LTZ, diversifying its long-term pipeline. Eli Lilly (LLY) Unveils Alzheimer's And CLL Trial Results With New LTZ Collaboration
• Negative Sentiment: Despite Mounjaro’s trial win, some analysts called the cardiovascular gains underwhelming relative to expectations. Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed
• Negative Sentiment: Jim Cramer disclosed selling some LLY shares, reflecting profit-taking on year-to-date gains. Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer
• Negative Sentiment: President Trump’s letters to 17 drugmakers on pricing, including Lilly, prompted a pullback in shares amid policy uncertainty. Eli Lilly’s stock drops as Trump targets 17 drug makers with letters on their pricing
• Negative Sentiment: Senators have questioned telehealth-drug company arrangements, raising regulatory risk around digital prescribing models. Senators raise questions about deals between telehealth and drug companies
• Negative Sentiment: Valuation concerns resurfaced in a Seeking Alpha piece arguing that Lilly’s strong growth prospects may already be priced in. Eli Lilly: The Best Growth Prospects Come At A Price